Skip to content

Study · Randomized controlled trial · n = 40 · 2025

4 results

Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.

Barakat KE, Abuhasan DK, Asal MF, Elsayed AAR, Mahmoud MR, Guy M, Safadi R, Basson MD

Obesity surgery10 Nov 2025Cited by 3 (Europe PMC)

PMID41212463 (opens in a new tab)PMCIDPMC12722407 (opens in a new tab)DOI10.1007/s11695-025-08368-5 (opens in a new tab)PepBankPUB-41212463
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

IntroductionGiven the global increase in obesity prevalence, there has been an emergence of a multitude of treatment options, specifically less invasive operations, like intragastric balloons, and pharmaceutical treatments like semaglutide. The aim of this study is to evaluate the synergistic effects of the intragastric balloon and semaglutide on weight reduction and weight regain.MethodsIn this prospective, randomized cohort, adults between the ages of 18 and 65, with a BMI of at least 27 kg/m², were assigned to one of two treatment groups: IGB only or IGB + semaglutide. Subcutaneous injections of semaglutide were administered with increasing dosages on a weekly basis in the second month and were continued after the removal of the intragastric balloon. All participants were monitored, and results were recorded at 3, 6, and 12 months.ResultsForty patients completed the study (n = 20 per group). The IGB + semaglutide group lost more weight than the IGB only group at 3, 6, and 12 months, with statistically significant differences at 6 months (29.09 ± 3.45 kg vs. 18.35 ± 2.80 kg, p < 0.001) and 12 months (33.03 ± 3.55 kg vs. 15.56 ± 2.50 kg, p < 0.001). After intragastric balloon removal at 6 months, the IGB only group regained previously lost weight while the IGB + semaglutide group continued to lose weight (2.79 ± 1.74 vs. -3.94 ± 2.16, p < 0.001).ConclusionAdjunctive semaglutide therapy with intragastric balloon (IGB) optimizes weight loss, while enhancing the sustainability achieved with intragastric ballooning alone. This combined therapeutic approach may provide an additional non-invasive intervention that provides optimal results and long-term weight loss maintenance.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and an intragastric balloon, adding semaglutide gave more weight loss at 3 months, but the difference was not stated as statistically significant.

    In plain wordsIn adults with a stomach balloon, those who also took semaglutide lost more weight at 3 months; no significance test is given.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss at 3 months
    Study

    n = 40

    Comparator
    Intragastric balloon (IGB) only
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    increasing weekly dosages · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The IGB + semaglutide group lost more weight than the IGB only group at 3, 6, and 12 months, with statistically significant differences at 6 months (29.09 ± 3.45 kg vs. 18.35 ± 2.80 kg, p < 0.001) and 12 months (33.03 ± 3.55 kg vs. 15.56 ± 2.50 kg, p < 0.001).
    2 context sentences
    Summary · context
    In this prospective, randomized cohort, adults between the ages of 18 and 65, with a BMI of at least 27 kg/m², were assigned to one of two treatment groups: IGB only or IGB + semaglutide.
    Summary · context
    Forty patients completed the study (n = 20 per group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and an intragastric balloon, adding semaglutide increased weight loss at 6 months compared with the balloon alone.

    In plain wordsIn adults with a stomach balloon, adding semaglutide led to more weight loss at 6 months than the balloon alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss at 6 months
    Study

    n = 40

    Comparator
    Intragastric balloon (IGB) only
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    increasing weekly dosages · subcutaneousAs given in this study (human).

    Measurements

    Weight loss
    29.09 kg
    IGB + semaglutide, 6 months
    Weight loss
    18.35 kg
    IGB only, 6 months

    Source sentences

    Summary
    The IGB + semaglutide group lost more weight than the IGB only group at 3, 6, and 12 months, with statistically significant differences at 6 months (29.09 ± 3.45 kg vs. 18.35 ± 2.80 kg, p < 0.001) and 12 months (33.03 ± 3.55 kg vs. 15.56 ± 2.50 kg, p < 0.001).
    2 context sentences
    Summary · context
    In this prospective, randomized cohort, adults between the ages of 18 and 65, with a BMI of at least 27 kg/m², were assigned to one of two treatment groups: IGB only or IGB + semaglutide.
    Summary · context
    Forty patients completed the study (n = 20 per group).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and an intragastric balloon, adding semaglutide increased weight loss at 12 months compared with the balloon alone.

    In plain wordsIn adults with a stomach balloon, adding semaglutide led to more weight loss at 12 months than the balloon alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss at 12 months
    Study

    n = 40

    Comparator
    Intragastric balloon (IGB) only
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    increasing weekly dosages · subcutaneousAs given in this study (human).

    Measurements

    Weight loss
    33.03 kg
    IGB + semaglutide, 12 months
    Weight loss
    15.56 kg
    IGB only, 12 months

    Source sentences

    Summary
    The IGB + semaglutide group lost more weight than the IGB only group at 3, 6, and 12 months, with statistically significant differences at 6 months (29.09 ± 3.45 kg vs. 18.35 ± 2.80 kg, p < 0.001) and 12 months (33.03 ± 3.55 kg vs. 15.56 ± 2.50 kg, p < 0.001).
    2 context sentences
    Summary · context
    In this prospective, randomized cohort, adults between the ages of 18 and 65, with a BMI of at least 27 kg/m², were assigned to one of two treatment groups: IGB only or IGB + semaglutide.
    Summary · context
    Forty patients completed the study (n = 20 per group).
  4. 04HumanRandomized controlled trialEfficacy outcome

    After balloon removal at 6 months, patients with the balloon only regained weight, while patients who also received semaglutide continued to lose weight.

    In plain wordsAfter the balloon was removed, people on the balloon alone regained weight, while people also taking semaglutide kept losing weight.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight change after balloon removal
    Study

    n = 40

    Comparator
    Intragastric balloon (IGB) only
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    increasing weekly dosages · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After intragastric balloon removal at 6 months, the IGB only group regained previously lost weight while the IGB + semaglutide group continued to lose weight (2.79 ± 1.74 vs. -3.94 ± 2.16, p < 0.001).
    2 context sentences
    Summary · context
    In this prospective, randomized cohort, adults between the ages of 18 and 65, with a BMI of at least 27 kg/m², were assigned to one of two treatment groups: IGB only or IGB + semaglutide.
    Summary · context
    Forty patients completed the study (n = 20 per group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.